Low molecular weight heparins: A guide to their optimum use in pregnancy

Drugs

Volumn 62, Issue 3, 2002, Pages 463-477

  Laurent, Pierre ^a   Dussarat, Guy Vincent ^a   Bonal, Jacques ^a   Jego, Christophe ^a   Talard, Philippe ^a   Bouchiat, Christian ^a   Cellarier, Gilles ^a  

^a Hôpital Ste Anne ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARDEPARIN; CERTOPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; TINZAPARIN;

BIOAVAILABILITY; BLEEDING; BLOOD PLACENTA BARRIER; CLINICAL TRIAL; COMORBIDITY; DRUG EFFICACY; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MILK LEVEL; DRUG MONITORING; DRUG SAFETY; EPIDURAL ANESTHESIA; FEMALE; FETUS MALFORMATION; HIGH RISK PATIENT; HUMAN; LABOR; LUNG EMBOLISM; OSTEOPENIA; PRACTICE GUIDELINE; PUERPERIUM; REVIEW; RISK ASSESSMENT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOPHILIA; TREATMENT PLANNING;

EID: 0036186840     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262030-00004     Document Type: Review

References (94)

1. Maternal mortality in Massachusetts: Trends and prevention
2. Venous thromboembolism and pregnancy
3. The special case of venous thromboembolism in pregnancy
4. Risks for the fetus of anticoagulant therapy during pregnancy
5. Heparin therapy during pregnancy: Risks for the fetus and mother
6. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
7. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis
8. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism
9. Thromboembolism and pregnancy
10. Low-molecular-weight heparins in pregnancy
11. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
12. Comparison of subcutaneous unfractionated heparin with a low molecular heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin
13. Current concepts of anticoagulant therapy in pregnancy
14. Low-molecular-weight heparins: An overview of their pharmacodynamics, pharmacokinetics, and metabolism in humans
15. Low molecular weight heparin: A critical analysis of clinical trials
16. Low molecular weight heparin
17. Low molecular weight heparin for obstetric thromboprophylaxis
18. Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
19. Bioavailability and antagonization of the low molecular weight heparin CY216 in man
20. Low molecular weight heparins (Kabi 2165, Fragmin®): Pharmacokinetics after intravenous and subcutaneous administration
21. Use of low molecular weight heparin in pregnancy
22. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: Study by direct fetal blood sampling under ultrasound
23. Low molecular weight heparin novo (LHN-1) does not cross the placenta during the second trimester of pregnancy
24. Lack of anti-factor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women
25. Placenta passage of low molecular weight heparin
26. The use of low molecular weight heparin for thromboprophylaxis in pregnancy
27. Low-molecular-weight heparin during pregnancy and delivery: Preliminary experience with 41 pregnancies
28. Thrombo-prophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies
29. Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy: A longitudinal safety study
30. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy
31. Bone density studies in pregnant women receiving heparin
32. Thromboembolic prophylaxis with low molecular weight heparin during pregnancy
33. A study of sixty pregnancies in patients with the antiphospholipid syndrome
34. Low molecular weight heparin as thromboprophylaxis in pregnancy
35. Obstetric outcome in antiphospholipid syndrome
36. High-dose intravenous immunoglobulin treatment of a pregnant patient with an antiphospholipid syndrome: Immunological changes associated with a successful outcome
37. Heparin-induced skin reaction due to two different preparations of low molecular weight heparin (LMWH)
38. Use of low molecular weight heparin for prophylaxis and treatment of thromboembolism in pregnancy
39. Low-molecular-weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk
40. Resistance to activated protein C and pregnancy: Thromboprophylaxis with low molecular weight heparin
41. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin
42. Anti-activated factor Xa profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin
43. Low-molecular-weight heparin for thrombophilia in pregnant women
44. Antenatal use of enoxaparin for prevention and treatement of thromboembolism in pregnancy
45. Low-molecular-weight heparin for immediate management of thromboembolic disease in pregnancy
46. Use of a low-molecular weight heparin (enoxaparin) or of a phenformin-like substance (moroxydine chloride) in primary early recurrent aborters with an impaired fibrinolytic capacity
47. Successful pregnancy outcome in a patient with both congenital hypofibrinogenemia and protein S deficiency
48. Deep venous thrombosis in a preterm newborn of a mother with activated protein C resistance
49. Retrospective evaluation of the safety and efficacy of low-molecular-weight heparin as thromboprophylaxis during pregnancy
50. Low molecular weight heparin as thromboprophylaxis in familial thrombophilia during the whole period of pregnancy
51. Thrombose, thrombopénie sous HBPM et délivrance
52. Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: A preliminary study
53. Thrombosis prophylaxis after treatment during pregnancy
54. Congenital antithrombin III deficient neonate treated with antithrombin III concentrates
55. Pharmacokinetic profile of a low-molecular weight heparin (reviparin) in pregnant patients: A prospective cohort study
56. Thrombocytopenia, antithrombin deficiency and extensive thromboembolism in pregnancy: Treatment with low-molecular-weight heparin
57. Low-molecular-weight heparin for treatment of pulmonary embolism in a pregnant woman
58. Deep venous thrombosis during pregnancy: Long-term treatment with low molecular weight heparin
59. Thrombosis laxis in an AT III deficient woman: Application of a low molecular weight heparinoid
60. Management of iliofemoral thrombosis in a pregnant patient with heparin resistance
61. Thromboembolism treated with low molecular weight heparin in a pregnancy complicated by major placenta praevia: A case report
62. Low-molecular-weight heparin and thromboembolism in pregnancy
63. Low-molecular weight heparin in venous thrombosis during pregnancy
64. Low molecular weight heparin treatment in a pregnant woman with allergy to standard heparins and heparinoid
65. Use of low molecular weight heparin during pregnancy
66. Assessment of a low molecular weight heparin (enoxaparin) safety during pregnancy: A retrospective study of 624 pregnancies
67. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: Study of 78 women
68. Thrombotic risk in hereditary antithrombin III protein C and protein S deficiency
69. Risk factors for pregnancy associated venous thromboembolism
70. Birth outcomes in pregnant women treated with low-molecular-weight heparin
71. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep vein thrombosis: A meta-analysis
72. Treatment of deep venous thrombosis with low molecular weight heparins: A meta-analysis
73. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a metaanalysis
74. Osteoporotic fractures and recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin
75. Prospective evaluation of bone density changes in pregnant women on low molecular weight heparin
76. Safety of low-molecular-weight heparin in pregnancy: A systematic review
77. Absence of transplacental passage of Fragmin (Kabi) during the second and third trimesters of pregnancy
78. Placenta transfer of glycosaminoglycans in the human perfused placenta cotyledon model
79. Use of antithrombotic agents during pregnancy
80. Heparin and low molecular weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
81. Hazards of heparin: Allergy, heparin induced thrombocytopenia and osteoporosis
82. Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium
83. Low-molecular-weight heparins
84. Thrombocytopenia associated with low molecular weight heparin
85. Low molecular weight heparin: Biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthetic management
86. Peripartum prophylaxis of thromboembolism
87. Low molecular weight heparins: Practical considerations
88. Low molecular weight heparin use during pregnancy: Issues of safety and practicality
89. Anticoagulant therapy of thromboembolic disease during pregnancy
90. Deep venous thrombosis and pulmonary embolism in pregnancy
91. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy
92. Prevention of thromboembolism in pregnancy
93. Antithrombotic therapy in high-risk pregnancy
94. Low molecular weight heparin for thromboprophylaxis during pregnancy in two patients with mitral valve replacement